- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
AlphaRx (OTC BB:ALRX - News) AlphaRx, a leader in the development of Nanotechnology for Drug Delivery Platforms, announced a major product launch in China. Through AlphaRx International Holdings (AIH), its Hong Kong affiliate, AlphaRx will launch Indaflex(TM) in 2008. Already a successful topical arthritis relief product in Mexico, AIH is building a plant in China to meet the expected demand. AIH will also produce Dicloflex(TM), an eye-drop formula used to treat ocular inflammation and pain, as well as Vansolin(TM) and Zysolin(TM), used for serious infections such as lung inflammation and nosocomial pneumonia, for the rapidly growing Chinese market. Michael Lee, chairman of AlphaRx, said, "this is the beginning of a major push into the world's biggest market. And with a permanent presence in Hong Kong through AIH, we are here to succeed over the short- and long-term."
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.
Forward Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.
For more information, please click here
Nucap Investor Relations
629 Fifth Avenue,Suite 300
Pelham, NY 10803
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015
Dyesol Joins Solliance as an Industrial Partner June 17th, 2015